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The Reality of Type 2 Diabetes
Prevention
Efforts to reduce the burden of type 2 diabetes include attempts to prevent or
delay the onset of the disease. Landmark clinical trials have shown that lifestyle
modification programs focused on weight loss can delay the onset of type 2
diabetes in subjects at high risk of developing the disease. Building on this
knowledge, many community-based studies have attempted to replicate the trial
results and, simultaneously, payers have begun to cover diabetes prevention
services. This article focuses on the evidence supporting the premise that
community prevention efforts will be successful. Unfortunately, no study has
shown that diabetes can be delayed or prevented in a community setting, and
efforts to replicate the weight loss achieved in the trials have been mostly
disappointing. Furthermore, both the clinical trials and the community-based
prevention studies have not shown a beneficial effect on any diabetes-related
clinical outcome. While the goal of diabetes prevention is extremely important,
the absence of any persuasive evidence for the effectiveness of community
programs calls into question whether the use of public funds or national
prevention initiatives should be supported at this time.
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Landmark clinical trials have shown that we can delay and possibly prevent the onset
of diabetes in many individuals at high risk (1,2). Encouraged by these results, there
have been many attempts to translate the prevention trials into community-based
programs. There have also been requests to expand diabetes prevention services
considerably (3–5). While diabetes prevention would be an invaluable benefit to
society, we must have confidence in our ability to translate the trials’ results using
far fewer resources and in real-world settings. Clinical trial results show what is
possible, but it cannot simply be assumed that their results can easily or cost-
effectively be translated into practice. In this article, we review many of the
important factors that must be considered before embarking on a nationwide effort
to delay or prevent the onset of diabetes. We show not only that the magnitude of
the task is daunting, but also that the efforts so far have been disappointing and that
essential information is missing.
An important issue to appreciate is the magnitude of the effort we will undertake.
Table 1 shows that between 6 and 38% of Americans (12.8–82 million people) have
“prediabetes,” depending on where the lower boundary is drawn and which test is
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used to make the diagnosis. All of the
cut points shown are arbitrary, since
there is no biological basis for any test
value at which prediabetes begins (6).
Even at the higher end of the range of
prediabetes (people with an A1C
between 6.1–6.4%), how this large
population will be identified and the
cost of the intervention itself become
very important. Thus, if nationwide
diabetes prevention efforts are to be
initiated, our first consideration is to
realize that the at-risk population is very
large and the cost of prevention could
amount to a great deal of money.
Although the above discussion implies a
nationwide effort to prevent diabetes,
for individuals who in the course of an
office visit are advised to lose weight
and do so on their own, the intervention
might obviously be well worth their own
money, if any is spent. But there is no
value to implementing a widespread
prevention program that does very little if
anything to reduce the development of
diabetes. Initiating diabetes prevention
should require confidence that society will
benefit and that the cost of such programs
will be money well spent. Thus, it is
imperative to ask whether there is
evidence that community-based
interventions will be effective.
CAN WE PREVENT OR DELAY
DIABETES OUTSIDE OF A CLINICAL
TRIAL?
Lifestyle Modification
The major prevention trials used either
“lifestyle modification” or
pharmacotherapy to significantly
reduce the incidence of diabetes.
Lifestyle modification was neither
simple nor straightforward. In the
Diabetes Prevention Program (DPP), the
primary goal was a reduction of at least
7% of initial body weight and an
enhanced level of physical activity in
overweight or obese people at high risk
of diabetes (1,7). In a post hoc study
analysis of the DPP, weight loss was by
far the most important contributor to
prevention (8). Reduction of calories
from fat and increased physical activity
predicted and helped sustain weight
loss (1,8). In the follow-up study of the
DPP, termed the DPP Outcomes Study
(DPPOS), the contribution of exercise to
prevention went unmentioned,
implying that this intervention was of
marginal value in preventing diabetes
(9). The Finnish Diabetes Prevention
Study (DPS) not only strived for weight
loss and increased physical activity in a
similar population but also sought many
changes in diet composition, such as a
reduction in saturated fat and an
increase in fiber intake (2). When all the
variables were analyzed simultaneously
“the only significant association was
between weight reduction and diabetes
risk” (10). Although dietary composition
and physical activity were important,
“their effect was mediated through
resulting weight reduction” (10). Other
randomized trials also show that weight
loss is the key, if not critical,
intervention to reduce diabetes risk
(11–13). Thus, weight loss appears to
take center stage when it comes to
lifestyle modification delaying the onset
of diabetes (14).
The Chinese Da Qing Diabetes
Prevention study also showed great
benefit in preventing diabetes through
lifestyle modification (15), although the
interventions were of questionable
value. In that study, weight loss was
minimal (;2 lbs) in the combined diet-
exercise arm after the initial 6-year
intervention; weight loss was actually
greater in the control arm after 20 years
of follow-up (16). Individuals
randomized to the exercise-only arm
showed a 46% reduction in the
incidence of diabetes after 6 years (15).
At baseline, however, the exercise
group was already doing 42% more
exercise than control subjects (casting
some doubt on the randomization
process); after the 6-year follow-up,
their exercise level did not improve
significantly from their baseline level. In
the 20-year follow-up report, no
information related to the exercise-only
group was reported (16).
Despite the impressive results of the
Chinese study (43% relative risk
reduction in the lifestyle group after
20-years follow-up), it is impossible to
translate the intervention used in this
study since neither a complete
description of the lifestyle changes that
occurred nor the identification of the
active component(s) are known. This
point was made by the investigators in
their discussion of the results (16).




110 mg/dL cut point
IFG with
100 mg/dL cut point A1C 5.7–6.4 A1C 5.7–6.0 A1C 6.1–6.4
n % n % n % n % n %
Total 27,412,000 12.5 82,225,000 37.5 56,554,000 25.9 43,792,000 20.0 12,763,000 5.8
Male 16,101,000 15.2 47,974,000 45.4 26,361,000 24.9 20,721,000 19.6 5,640,000 5.3
Female 11,311,000 10.0 34,251,000 30.2 30,193,000 26.8 23,071,000 20.4 7,123,000 6.3
Mexican American 2,219,000 11.8 7,155,000 38.1 5,342,000 28.5 4,244,000 22.6 1,099,000 5.9
Other Hispanic 855,000 7.4 3,864,000 33.5 3,065,000 26.8 2,410,000 21.1 655,000 5.7
Non-Hispanic white 20,118,000 13.5 57,004,000 38.3 35,969,000 24.2 27,764,000 18.6 8,205,000 5.5
Non-Hispanic black 3,102,000 12.7 8,736,000 35.6 8,890,000 36.8 6,604,000 27.3 2,286,000 9.5
Other 1,118,000 7.3 5,466,000 35.6 3,288,000 21.4 2,770,000 18.0 518,000 3.4
Age 20–49 years 9,669,000 7.8 39,249,000 31.5 21,148,000 17.0 17,832,000 14.3 3,316,000 2.7
Age 50–64 years 9,383,000 17.1 24,269,000 44.3 18,219,000 33.3 14,150,000 25.9 4,069,000 7.4
Age $65 years 8,359,000 21.1 18,708,000 47.3 17,188,000 43.3 11,810,000 29.8 5,377,000 13.6
Table was generated from the National Health and Nutrition Examination Survey 2009–2010 data. IFG, impaired fasting glucose.
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In summary, it appears that weight loss
is the key factor that reduces diabetes
risk, and thus all efforts to translate the
prevention trials to a community setting
have focused on weight reduction.
While exercise may be important, aside
from the Chinese study results, which
are inconclusive, we have no
randomized controlled studies showing
the benefit of exercise alone on diabetes
prevention or what type of exercise or
for how long (i.e., overmonths or years) is
key. Ali et al. (17) recently summarized
all the lifestyle interventions initiated in
real-world settings that have been
modeled on the DPP. They identified 28
studies but only 4 were carried out for
12 months or longer, and none of those
reported the incidence of diabetes.
In addition to the four longer-term
studies identified by Ali et al. (17), we
performed a broad literature search
using PubMed and Embase to identify
randomized, controlled trials
demonstrating the effectiveness of
delivering behavioral weight loss
interventions to overweight or obese
adults in a community setting that had
at least 1 year of follow-up (18–30).
Table 2 shows the degree of weight loss
seen in the intervention group over that
seen in the control group in all the
community studies we identified
(18–30) and in the twomajor prevention
trials. There are two important points to
be gleaned from these studies. One is
that where data were collected beyond
1 year, weight regain begins,
commencing about that time. Of note,
however, in the studies by Katula et al.
(23,24), subjects regained virtually no
weight in year 2, which is surprising
given the fact that no other weight loss
study using lifestyle modification was
nearly as successful (1,2,21,22,27,31).
The results from Katula et al. (23,24)
may, however, have been an artifact
due to the fact the year 2 weight
assessment was done on those
returning for that examination (n = 127
or a 16% drop-out rate in the
intervention arm; 11% drop-out rate in
control subjects), whereas the baseline
assessment was made on the entire
starting cohort (n = 151).
Weight regain is very common in weight
loss studies that use a behavior
intervention. Thus, it is extremely
difficult to maintain weight loss, even in
studies where the intervention is still in
full force and the enrollees are
extremely well motivated. Weight
regain is thought to occur because of the
physiologic drive to return to one’s
previous weight (32–34).
The other key finding shown in Table 2 is
that the degree of weight loss in the first
year of the vast majority of the
community programs was less than that
achieved in the prevention trials at the
equivalent period. Overall, weight loss in
most community settings at year 1 was
about the same as that achieved in the
later years of the major trials. The most
notable exception again was the studies
by Katula et al. (23,24), in which weight
loss at year 2 was the closest to what was
achieved in the study it attempted to
translate (i.e., DPP). Notwithstanding
potential issues related to the
measurement of weight loss over the
2-year follow-up, as mentioned above,
the results of the Katula studies’ (23,24)
intervention may have promise if the
weight loss achieved at year 2 can be
sustained and replicated.
There are other reports that are relevant
to weight loss in community settings.
Finland has initiated a large-scale
nationwide diabetes prevention
program modeled after the DPS (35).
The interim report of that effort showed
that after 1 year, participants on
average lost very little weight (mean
1.3%); only 18% of the cohort lost $5%
of their body weight compared with
nearly 50% of participants in the original
DPS (2). Thus, the translation study
could not achieve the same degree of
weight loss as in the prevention trial.
Compared with those who maintained
their weight, people losing 2.5–4.9%
body weight had only an 18% risk
reduction, comparedwith a 58% relative
risk reduction in the DPS after 3 years of
follow-up. Also, there are widely
available commercial weight loss
programs that could be considered
community-based interventions. These
reports show that some participants can
lose 3–4% of their body weight in the
first year of enrollment (36,37).
The inability of nearly all the community
studies to come close to replicating the
weight loss achieved in year 1 of the
prevention trials and the steady weight
regain thereafter is troublesome.
Moreover, as the lifestyle intervention in
all the community studies was provided
free, subjects received a great deal of
staff-directed encouragement
throughout the study and were likely to
be a more highly motivated group. Such
important benefits are unlikely to be
provided outside of a study environment.
How Much Weight Loss Protects
Against Diabetes?
There appear to be no data directly
documenting the relationship between
Table 2—Percent of weight loss over that achieved in standard weight-loss program
control subjects
Study Year 1 Year 2 Year 3 Year 4 Year 5




Wadden (21) 1.4 1.3
Appel (22) 4.5 4.0
Katula (23)
Katula (24) 5.1 5.0
Heshka (25) 3.2
Kulzer (26) 2.6





DPP/DPPOS (1,9)** 7.4 5.6 4.2 3.2 2.1
DPS (2,10) 4.4 3.7 2.9 2.1
*Data are from 15months of follow-up. **There was essentially no weight loss or weight gain in
the control group.
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weight loss and diabetes prevention.
Hammen et al. (8) reported that every
kilogram of weight loss in the DPP
resulted in a 16% reduction in risk, but
their results were based entirely on data
from the initial 3 years of the study. As
the mean weight loss diminishes with
time, so would the relationship between
absolute weight reduction and risk of
diabetes. In the DPS (10), the relative
risk reduction in the cumulative
incidence of diabetes was 36% when
only the 3-year postintervention period
was analyzed, which narrowly made
statistical significance (P , 0.04). In the
first year of the 3-year postintervention
period (which corresponds to DPS year 5
data in Table 2), weight reduction was
2.1% relative to control subjects. It is
very possible that as weight regain
occurred in DPS (and DPP too); the
cumulative incidence data over the
initial years mask a much lower
difference between groups in the
annual incidence of diabetes in
subsequent years. In fact, at year 4 of
the DPS, fasting plasma glucose levels
had returned to baseline values and
continued to increase thereafter (38).
Other data support the hypothesis that
weight loss of at least 3–4% over an
extended period of time is necessary to
achieve appreciable diabetes
prevention. At the start of the DPPOS,
the weight of individuals in the lifestyle
arm was about 3–4% less than control
subjects (9), and the incidence of
diabetes was no different thereafter
between the lifestyle and control arms.
It was not entirely clear, however,
whether the absence of a protective
effect was due to the smaller
percentage of weight lost relative to the
DPP or due to other factors identified in
the follow-up report (9). Also in the
DPP/DPPOS (1,9), the mean A1C level in
the lifestyle arm was lowest when
weight loss was at its maximum
(i.e., year 1); A1C levels increased
thereafter, seeming to correlate with
the degree of weight regain (9).
In a computer simulation of the DPP (39)
that relied only on the baseline data of
the DPP participants and the degree of
weight loss, the incidence of diabetes
mimicked the results of the DPP (1) and
DPPOS (9). The simulation assumed a
mean weight loss of 7% in year 1,
gradually decreasing to 4% weight loss
after 3 years (as seen in the DPP), and
held at that level for decades. After
10 years of follow-up in the simulation,
the incidence of diabetes in the lifestyle
group was virtually the same as that
achieved in the DPP. If the 4% weight
loss in the simulation was maintained
for 30 years, the risk of diabetes was
reduced by a relative 15%. These data
confirm that the benefit of lifestyle
modification was due mainly to weight
loss and that a 4% weight reduction for
life would be beneficial.
Finally, in a study to determine whether
bariatric surgery could prevent the
onset of type 2 diabetes, after 15 years
of follow-up there was an 83% relative
reduction in the incidence of diabetes,
and that corresponded to a relative 17–
26% loss in body weight over the entire
follow-up period (40).
Although the information above on the
relationship between weight loss and
diabetes prevention is not definitive, it
does suggest that the delay in
developing diabetes is relatively
proportional to weight loss. Since nearly
all the real-world studies could only
achieve a weight loss in year 1 that
corresponded to years 3–4 in the
prevention trials and weight regain after
year 1 is assured, it is likely that very
few cases of diabetes would be
prevented in community programs,
particularly over more than just a couple
of years. Unfortunately, none of the
community studies were designed to
determine the extent to which diabetes
is prevented; all report only surrogate
end points. So, in fact, we will not know
the clinical benefit of modest weight
loss anytime soon, but all the indirect
evidence points to a greatly diminished,
or absent, long-term benefit.
Pharmacotherapy
Many studies show that glucose-
lowering drugs can delay the onset of
diabetes (41). With the exception of
metformin, none of the drugs have been
given for more than 3 years. After their
discontinuation, the incidence of
diabetes increases. In the DPP,
metformin was given for 3 years and
resulted in a 31% reduction in the
incidence of diabetes (1). The delay to
the onset of diabetes was estimated to
be half that achieved in the lifestyle
group (9). About 75% of the participants
in the metformin arm took what was
considered to be the prescribed dose,
but in the follow-up study the rate of
adherence dropped to 57% (9).
Considering safety and cost, metformin
appears to be the best drug to reduce
the incidence of diabetes, but success
requires adherence to long-term
treatment, which appears problematic
and even less likely among individuals
not enrolled in a clinical trial. While
some investigators suggest using a
combination of glucose-lowering drugs
(42), such regimens have not been
tested. Newer drugs (43) hold promise
in their ability to promote weight loss
and improve cardiovascular risk factors,
but they are very expensive and have
not been given to individuals with
prediabetes for long periods of time.
Despite the above considerations, if
drugs are to be routinely used in people
with prediabetes, then essentially we
have moved the diagnostic cut point for
diabetes to a lower level. While that
may be warranted, all the ramifications
of such a change deserve considerable
discussion.
THE IMPACT OF DIABETES
PREVENTION ON CLINICAL
OUTCOMES
Lifestyle intervention in the DPP and
DPS resulted in an overall mean delay in
the development of diabetes of about
4–5 years; pharmacotherapy, 2 years
(9). Since the primary goal of diabetes
prevention is a reduction in diabetes-
related complications, it is important to
know how valuable a 4–5 year delay is in
preventing the clinical outcomes of
interest. In their initial intervention
periods (;3 years), both the DPS (2) and
DPP (44) observed significant reductions
in some surrogate biomarkers. Systolic
blood pressure and triglyceride levels
were significantly reduced but not total
cholesterol or LDL. In the DPPOS (9,45),
the risk factor reductions initially
observed were not maintained by the
end of the extended follow-up period.
More important, after 7 years of follow-
up in the DPS and 10 years follow-up in
the DPP, no significant change in any
clinical outcomes between the
intervention and control arms have
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been reported. With one exception, no
clinical outcome benefits using
pharmacotherapy to prevent diabetes
have been reported. In the Study to
Prevent Non-Insulin-Dependent
Diabetes Mellitus (STOP-NIDDM) trial, a
reduction in cardiovascular events was
reported, but the overall event rate was
very low and the finding was not
considered important to even mention
by those reviewing pharmacologic
options to prevent diabetes (14,42).
Two other studies provide evidence
that a considerable degree of weight
loss is necessary to see clinical value. In
the Action for Health in Diabetes (Look
AHEAD) trial (31), a study to determine if
weight loss in people with diabetes will
reduce cardiovascular events, weight
loss after the first year was substantial
(7.9% relative to control subjects) and at
year 4 the intervention group had lost
3.6% of their initial body weight relative
to control subjects. Nevertheless, after
many years of follow-up, the study was
halted because there was no benefit of
weight reduction on cardiovascular
events (46).
Conversely, following bariatric surgery
that resulted in a 17%mean loss in body
weight after a median 15 years of
follow-up, first-time fatal and nonfatal
cardiovascular events declined 33% and
overall cardiovascular deaths declined
by 53% compared with nonsurgical
control subjects (47). Although there
was an approximate 20% reduction in
weight 1 year following surgery, the
benefit in outcomes between the two
groups was not seen until year 6. In the
modeling study referred to previously
(39), a 4% weight loss maintained for
decades resulted in a small but
important reduction in diabetes-related
complications.
As the weight loss achieved in
community-based programs is usually
much less than was achieved in DPP,
DPS, or Look AHEAD, many-fold less
than in the surgical study, and very likely
notmaintained formany years, the odds
of a community diabetes prevention
program having a favorable impact on
cardiovascular disease or other
diabetes-related complications seem
slim. There may be other potential
benefits of a community prevention
program independent of preventing
diabetes or its complications, such as
work productivity, but there is no
evidence of such benefits or if they
would remain once weight regain
occurs.
Is Diabetes Prevention Cost-effective?
Some participants in community-based
programs will surely not progress to
diabetes, but what matters most is
whether a few successes make the
entire effort cost-effective. There are
many reports claiming that diabetes
prevention programs can be or are cost-
effective (39,48–51). In order to achieve
such a benefit, all of the reports posit
that the lifestyle intervention would
cost far less than it did in the DPP and,
more remarkably, achieve weight loss
results equivalent to the DPP (7%
initially declining to ;4%, relative to
control subjects) that would not
diminish over at least 30 years. As
discussed previously, that has not yet
happened in real life. Also, cost-
effectiveness is achieved when the time
horizon is about 30 years or more, but
not in the first 10–15 years of the
program. As a result, these studies do
not actually represent an outcome that
health plans or a national program
would actually experience in a time
frame more familiar to planning and
budgeting or to the clinical outcomes
people are likely to experience. Also,
with one exception (39), all the
modeling studies use a Markov model,
which represents diseases as a set of
discrete clinical “states,” progression of
disease as annual transitions between
states, and the effects of treatments as
changes in the likelihood of transitions
between states. In order to fit a complex
disorder such as diabetes into the
Markov structure, a great many
assumptions and simplifications must
be made that are unrealistic (see
appendix to ref. 39). In the only cost-
effectiveness study (39) that used a
model validated against a great many
clinical trials, the results indicated that
cost-effectiveness after 30 years
required an intervention costing no
more than about $200/year and weight
loss of 4% over that entire period.
The above critique highlights that a
claim of cost-effectiveness for a
program achieving hypothetical results
over an unrealistic time frame and
using, as in most studies, many
unrealistic assumptions is at best an
abstraction. An analysis of actual costs
was recently reported by the DPP/
DPPOS investigators (52). Their data
show that the total cost of medical care
during a median 8.5 years follow-up was
modestly higher in the placebo group
than in the lifestyle group (per capita
difference of $291/year), but the cost of
the intervention itself wiped out this
benefit. If the cost of the lifestyle
intervention had been much less (and
assuming there would be the same
degree of weight loss) or if metformin
were used, the total cost might favor
diabetes prevention services. Of course,
by far and away the costly part of
diabetes is in the treatment of its
complications, and in the initial 8.5
years of the DPP/DPPOS very few
serious diabetes-related complications
occurred in any group (9). Without
knowing whether the DPP interventions
reduce the costly events associated with
diabetes, it is too premature to conclude
that the DPP, or more important a less
robust DPP-like intervention as
experienced in community programs, is
cost-effective.
THE FUTURE OF DIABETES
PREVENTION
Although we know how to postpone the
onset of diabetes, the resulting benefit
is not altogether clear and translating
the information to a community setting
has been elusive. Although some people
can lose weight and keep it off even
without any structured programmatic
help and some may be able to maintain a
lifestyle modification program that, by
whatever means, delays the onset of
diabetes, the success rate of either
appears to be very low in the real world.
And if the diagnosis of diabetes is delayed
by 2–5 years as in the trials, it is still
uncertain that such a delay, absent
greater weight loss maintained for a very
long time (39), will reduce the rate of
serious adverse clinical events. Although
other components of a lifestyle
modification may be valuable (e.g.,
exercise or a change in diet composition),
we do not have good trial data showing
how they would be effective in changing
the course of prediabetes. Nor do we
know if such changes in of themselves as
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elements of a diabetes prevention
intervention have long-term clinical
benefits that would ultimately make
prevention services beneficial in other
ways.
Too much information is missing to
implement nationwide, community-
based diabetes prevention programs, as
has been suggested (3,4,50,51). We
should at least have good evidence
that a specific lifestyle or pharmacologic
intervention will lead to substantial
weight reduction maintained for at least
10 years. Then we need realistic cost-
effectiveness studies. Given the
evidence to date, it also seems unlikely
that current lifestyle modification
programs can both overcome our
obesogenic environment and remain
effective for very long.
The previous discussion does not at all
mean we should abandon efforts to
replicate the results of the prevention
trials. Nor should we discourage
individuals from attempting weight loss
using their own resources, even
knowing that relatively few will be
successful at sustaining meaningful
weight loss. Indeed, providers should
routinely encourage their overweight/
obese patients to lose weight and
provide referral to institutions that may
be of benefit. In addition, we certainly
have an imperative to prevent diabetes
and to continue experimenting with
various approaches to translating the
major clinical trials. Equally important,
we need to better understand the
clinical value of various amounts of
weight loss. Since most studies had
participants who achieved and
maintained considerable weight loss, it
would be valuable to be able to identify
such individuals before an intervention
is given to an entire population. Also, we
should experiment with novel
approaches to behavior modification
(53). But our failure so far to come close
toward replicating the major prevention
trials in community-based settings
strongly suggests that it is premature to
siphon off precious national health care
resources or revenue going into health
plans toward an intervention that has
no clear clinical benefit.
Although bariatric surgery in the obese
is very effective in preventing diabetes
(40) and some important diabetes-
related complications (48), surgery is an
impractical choice for most people with
prediabetes. Finally, it may be more
beneficial to achieve diabetes
prevention by attacking the problem
through national policies that reduce
our overall consumption of food (54,55).
In the long run, a societal solution (not a
medical one) to the obesity/diabetes
epidemic may end up being the best
option.
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